Spectrum Solutions Collaborates with UCLA on Saliva-Based Next-Gen Sequencing (NGS) Liquid Biopsy Research for the Early Detection of Lung Cancer
January 28, 2021
Study to focus on using saliva in the analysis of cell-free circulating tumor DNA (ctDNA) to accurately and non-invasively detect non-small cell lung cancer (NSCLC).
“SALT LAKE CITY–(BUSINESS WIRE)–Spectrum Solutions, LLC today announced its sponsored research collaboration with the UCLA School of Dentistry for a study on using saliva in early lung cancer detection and analysis. Spectrum has funded a study that aims to recruit 50 patients with lung cancer and seeks to validate saliva’s tumor-specific ctDNA detection sensitivity and positive agreement against tissue biopsy-based genotyping. Saliva will be collected, preserved, and transported for DNA testing using Spectrum’s Saliva Collection System. The company will further support the development of clinical methods and additional technical innovations.” Read the full article through the link below.
Recent News
- Rep. Celeste Maloy Tours BIOS, Neurotech Innovation
- U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome
- Sera Prognostics Appoints Scott Gleason CFO
- Merit Medical Announces Global Operations Leadership Transition
- Utah Life Sciences Innovation Caucus Breakfast
- Curavit Expands Clinical Research Capabilities with Acquisition of Lindus Health CRO Assets, Accelerating Global Trial Execution for Life Science Sponsors
